REG - Allergy Therapeutics - NOTICE OF 2022 ANNUAL GENERAL MEETING

Allergy TherapeuticsAnnouncement

13/01/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230113:nRSM7383Ma&default-theme=true

RNS Number : 7383M  Allergy Therapeutics PLC  13 January 2023

13 January 2023

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

 

NOTICE OF 2022 ANNUAL GENERAL MEETING

 

 

Allergy Therapeutics plc has today published it's Notice of 2022 Annual
General Meeting.   It is available electronically on the Company's website
at www.allergytherapeutics.com (http://www.allergytherapeutics.com)

 

A hard copy of the Notice of Meeting has been posted to shareholders on 13
January 2023.

 

 

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0)1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0)20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

 

 

 

Notes for editors:

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology group
focussed on the treatment and diagnosis of allergic disorders, including
immunotherapy vaccines that have the potential to cure disease. The Group
sells proprietary and third party products from its subsidiaries in nine major
European countries and via distribution agreements in an additional fourteen
countries. Its broad pipeline of products in clinical development include
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which has
achieved 10% compound annual growth since formation, employs c.500 employees
and is listed on the London Stock Exchange (AIM:AGY). For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAZZGMMNFVGFZM